DK1115290T3 - Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf - Google Patents

Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf

Info

Publication number
DK1115290T3
DK1115290T3 DK99969648T DK99969648T DK1115290T3 DK 1115290 T3 DK1115290 T3 DK 1115290T3 DK 99969648 T DK99969648 T DK 99969648T DK 99969648 T DK99969648 T DK 99969648T DK 1115290 T3 DK1115290 T3 DK 1115290T3
Authority
DK
Denmark
Prior art keywords
gene delivery
methods
delivery system
tissue
cell
Prior art date
Application number
DK99969648T
Other languages
Danish (da)
English (en)
Inventor
Nori Kashahra
Christopher Logg
W French Andersen
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK1115290T3 publication Critical patent/DK1115290T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Body Suspensions (AREA)
DK99969648T 1998-10-01 1999-10-01 Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf DK1115290T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10293398P 1998-10-01 1998-10-01
PCT/US1999/023016 WO2000018240A1 (en) 1998-10-01 1999-10-01 Gene delivery system and methods of use

Publications (1)

Publication Number Publication Date
DK1115290T3 true DK1115290T3 (da) 2009-06-22

Family

ID=22292475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99969648T DK1115290T3 (da) 1998-10-01 1999-10-01 Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf

Country Status (9)

Country Link
US (4) US6410313B1 (de)
EP (3) EP1115290B1 (de)
AT (1) ATE424114T1 (de)
AU (1) AU1441900A (de)
CA (1) CA2346931C (de)
DE (1) DE69940521D1 (de)
DK (1) DK1115290T3 (de)
ES (1) ES2323744T3 (de)
WO (1) WO2000018240A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
AU1441900A (en) * 1998-10-01 2000-04-17 University Of Southern California Gene delivery system and methods of use
CA2371946A1 (en) * 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
IL160132A0 (en) * 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en) 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
CN100398649C (zh) * 2002-05-31 2008-07-02 浙江养生堂天然药物研究所有限公司 一种人白血病相关逆转录病毒基因组核酸序列及其应用
WO2004050829A2 (en) * 2002-08-20 2004-06-17 Aeras Global Tuberculosis Vaccine Foundation Recombinant double-stranded rna phage, and use of the same
US7927599B2 (en) * 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8257963B2 (en) 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
CN101065492A (zh) * 2004-11-24 2007-10-31 纳诺非科特有限公司 病毒载体
KR101950635B1 (ko) 2008-06-30 2019-05-20 토카겐 인크. 5-플루오르시토신 제제 및 이의 용도
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
JP5771147B2 (ja) 2008-09-26 2015-08-26 トカジェン インコーポレーテッド 遺伝子治療ベクターおよびシトシンデアミナーゼ
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
DK3159415T3 (en) 2009-06-17 2019-04-23 Tocagen Inc Production cells for replicative retroviral vectors
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
JP6419706B2 (ja) * 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
JP6640717B2 (ja) 2013-06-15 2020-02-05 トカジェン インコーポレーテッド レトロウイルス複製ベクターと関連する免疫抑制成分
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
EP3413926A4 (de) 2016-02-08 2019-10-09 American Gene Technologies International, Inc. Hiv-impfung und immuntherapie
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
EP3487507A4 (de) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. Virale vektoren zur behandlung der parkinson-krankheit
EP3607072A4 (de) 2017-04-03 2021-01-06 American Gene Technologies International Inc. Zusammensetzungen und verfahren zur behandlung von phenylketonurie

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6241982B1 (en) * 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
EP0361749B1 (de) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
WO1993003143A1 (en) 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
DE69333471T2 (de) * 1992-11-09 2005-02-24 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Erzielbare vektorenpartikel
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US6033905A (en) * 1993-04-06 2000-03-07 The United States Of America As Represented By The Department Of Health And Human Services Gibbon ape leukemia virus-based retroviral vectors
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US20030157070A1 (en) * 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) * 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
AU758155B2 (en) * 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6291214B1 (en) * 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
FR2778670B1 (fr) * 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
AU4089899A (en) * 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
US6322969B1 (en) * 1998-05-27 2001-11-27 The Regents Of The University Of California Method for preparing permuted, chimeric nucleic acid libraries
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
AU1441900A (en) * 1998-10-01 2000-04-17 University Of Southern California Gene delivery system and methods of use
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) * 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
CA2371946A1 (en) * 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059356B1 (de) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
EP1059357A1 (de) * 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replizierende oder 'semi-replizierende' retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
US8163893B2 (en) 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
AU7521500A (en) * 1999-11-30 2001-06-12 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001292711A1 (en) * 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
US20030003565A1 (en) * 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
US7226779B2 (en) * 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
WO2002092786A2 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
US7211247B2 (en) * 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) * 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) * 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
FR2832424B1 (fr) * 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
AU2003206815A2 (en) * 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
CA2524892A1 (en) * 2002-05-17 2003-11-27 Retrovec Aps A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) * 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
CN101065492A (zh) * 2004-11-24 2007-10-31 纳诺非科特有限公司 病毒载体
US8557971B2 (en) 2006-03-17 2013-10-15 Aarhus Universitet Chimeric viral envelopes
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
KR101950635B1 (ko) 2008-06-30 2019-05-20 토카겐 인크. 5-플루오르시토신 제제 및 이의 용도
JP5771147B2 (ja) 2008-09-26 2015-08-26 トカジェン インコーポレーテッド 遺伝子治療ベクターおよびシトシンデアミナーゼ

Also Published As

Publication number Publication date
ATE424114T1 (de) 2009-03-15
CA2346931C (en) 2011-11-29
EP1115290A4 (de) 2002-12-04
AU1441900A (en) 2000-04-17
CA2346931A1 (en) 2000-04-06
US6410313B1 (en) 2002-06-25
US20020127697A1 (en) 2002-09-12
WO2000018240A1 (en) 2000-04-06
EP1115290A1 (de) 2001-07-18
US8652460B2 (en) 2014-02-18
EP2386646B1 (de) 2016-12-21
EP1932426A1 (de) 2008-06-18
US20140234958A1 (en) 2014-08-21
US20120052554A1 (en) 2012-03-01
EP2386646A1 (de) 2011-11-16
ES2323744T3 (es) 2009-07-23
US8741279B2 (en) 2014-06-03
DE69940521D1 (de) 2009-04-16
EP1115290B1 (de) 2009-03-04

Similar Documents

Publication Publication Date Title
DK1115290T3 (da) Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf
WO2003060101A3 (en) Gene delivery system and methods of use
DK458480A (da) Dna, recombinant plasmid og mikroorganisme indeholdende dette samt fremgangsmaader til fremstilling deraf
DK136184D0 (da) Fremgangsmaade til udtrykkelse af et gen,der koder for prochymosin,i e.coli-vaertsceller og udtrykkelsesplasmid til brug ved fremgangsmaaden
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
FI961755A (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
DE59800697D1 (de) Feuerfester werkstoff auf basis chromkorund, chromkorund-stein sowie verwendung des steins
DE69941049D1 (de) Retrovirales verabreichungssystem
DK0599868T3 (da) Polyphenoloxidase-gener
NO862975D0 (no) Kvaternaere oksalkylerte polykondensater, fremgangsmaate til deres fremstilling, og deres anvendelse.
DK610884A (da) Humant interferon-gamma-polypeptidderivat, fremgangsmaade til fremstilling deraf og rekombinant plasmid indeholdende et dna-fragment, derkoder for polypeptidet
NO862976D0 (no) Oksalkylerte polyesteraminer, fremgangsmaate til deres fremstilling og deres anvendelse.
DK155184D0 (da) Humant interferon-gamma-polypeptid og fremgangsmade til fremstilling deraf, rekombinant plasmid omfattende et dna-fragment, som koder for peptidet, og mikroorganisme transformeret med plasmidet
DK47887A (da) Vektor til transfektion af en celle til opnaaelse af et hoejt genekspressionsniveau
DE60039032D1 (de) Regulatorische konstrukte, die das intron 3 des pr
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
FI884556A (fi) Rekombinantplasmid-dna ppr-ifn 1-13, som kodas foer syntes av maenniskans fibroblast- 1-interferon, foerfarande foer framstaellning daerav och e.coli innehaollande detta.
SE8602945D0 (sv) Kopplingsmedel for termoplaster och oorganiska armeringsmedel
ATE408686T1 (de) Chondrosarcom-assoziierte gene
COOK BLOCKLEYS' CLAY PAVIORS- THE TOTAL CONCEPT.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.